2026-10-04 · 2026-10 / week-1

JAGX’s Series R Dividend Adds a Shareholder Clock, Not a Bounded Short

JAGX’s Series R Dividend Adds a Shareholder Clock, Not a Bounded Short

No-trade screen: Reject. Jaguar Health announced a Series R preferred-stock dividend after the Oct. 2 regular close, with an Oct. 13 record date and Nov. 2 conversion into five common shares per preferred share. Its release did not state how many preferred shares each eligible common share receives; the complete Series R terms were still absent from the issuer’s SEC-filings page at this review. A separate proxy describes outstanding preferred/debt exchanges that, if approved and fully exercised, could add 1.8 million to 25.4 million common shares depending on hypothetical exchange price. That is not a forecast or a completed issuance. At $3.66, the highest-probability short case is flat; a previously reported $41.53 post-split high implies a +1,034.7% adverse stress. Reject before execution.

Publication time: 2026-10-04 19:45 Asia/Singapore | Scope: U.S. market, short opportunities only | Format: No-trade screen | Classification: Reject / no trade

Opportunity Ranking

Rank Candidate Direction Mispricing Evidence Freshness Catalyst Window Positioning 10/5 Status Tradeability Main Rejection Risk
1 Jaguar Health (JAGX) Short Management describes the Series R dividend as dilution protection, but the release omits the preferred shares-per-common ratio; a separate proxy details potentially massive, conditional debt/preferred exchanges Oct. 2 issuer release; Sep. 24-28 SEC filings; Sep. 29 amended preliminary proxy; Oct. 2 split-adjusted market history First post-disclosure regular session Oct. 5; Series R record date Oct. 13, payment Oct. 15, conversion Nov. 2; separate vote Nov. 6 1.212M common shares were issued in recent note exchanges, but subsequent resale, current short interest, borrow and holder flows are unknown Reject: 0% base decline, +1,034.7% reported high stress, 0:1 gross base/adverse About $2.11M regular-session reference turnover; live spread, depth, locate and borrow unverified Missing Series R ratio; conditional conversions, strategic alternatives and microcap volatility can overwhelm a dilution thesis
2 60 Degrees Pharmaceuticals (SXTP) Short Oct. 6 DSMB interim analysis is imminent; Oct. 2 close rose 11.2% after the date was confirmed Oct. 1 and July 29 issuer releases; Q2 10-Q; Oct. 2 market records Oct. 6 interim data release and investor webinar About 196K shares on Oct. 2; current locate, borrow and short-interest settlement not checked Reject: binary outcome leaves >5% squeeze path unbounded About $278K reference turnover; spread, depth and exit capacity unverified A favorable primary-endpoint result could prompt early stopping and sharp repricing
3 NeuroSense Therapeutics (NRSN) Short Nasdaq’s $35M market-value deficiency is appealable; the issuer says a timely hearing request stays suspension and separately reports restored $1 bid-price compliance Oct. 2 issuer update and Oct. 2 regular close Hearing/Panel process; ALS Phase 3 remains a separate positive catalyst No current short interest, borrow or ownership flows verified Reject: appeal stay and clinical upside defeat a bounded adverse path $3.935 close on about 24K shares; thin turnover Additional compliance time or clinical news may squeeze a low-liquidity short
Control SPDR S&P 500 ETF (SPY) Broad-market control The S&P 500 rose 0.7% on Oct. 2; index strength is context, not a JAGX valuation input Oct. 2 regular close None specific Not scored Not a short finalist Liquid broad-market control Index performance cannot resolve JAGX’s preferred, debt or strategic states

Selected opportunity: JAGX, for information value only. This is not a qualified or executable short.

Why this one now: The July 29 Desk note focused on JAGX’s 40.8 million-share ELOC resale registration and the preceding quarter’s runway warning. The boundary has materially changed: JAGX effected a 1-for-15 reverse split, issued common shares for debt exchanges in late September, filed a new proxy describing conditional preferred/debt conversions, and then announced a new Series R stock dividend after the Oct. 2 close. The new dividend’s share ratio is not yet disclosed. This screen tests the newer vote, exchange and preferred-distribution path, not whether the old ELOC headline implies immediate resale. The earlier note is “Jaguar Health Prices a Drug Story, Not a 40.8 Million-Share Equity Line”.

Same-name calibration check: The July 29 Desk note used a $0.97 reference and a $1.35 adverse target over a 2–8 week window. Applying the Sep. 17 1-for-15 reverse split converts these to $14.55 and $20.25 in current-share units. StockAnalysis reports a Sep. 22 intraday high of $41.53, a +185.4% adverse excursion from the adjusted reference and above that prior stress. The Sep. 23 close of $8.91 implies a +38.8% paper short price return at the prior window’s end, between its $8.25 top and $11.70 base targets. That earlier signal had null entry and execution blocked: this was not an executed loss, but the interim adverse bound failed. It is why the current screen rejects any claim of bounded short risk.

What should surprise the reader: The latest SEC-filed common count was 1,945,542 on Sep. 25, not the 520,140 shown by one market-statistics vendor. In the same proxy, Jaguar illustrates possible issuance of 1.81 million to 25.39 million shares upon a full exchange of Series Q preferred and certain CVP debt, depending on hypothetical exchange price. Those amounts require a Nov. 6 shareholder vote and later exchange actions; they are not today’s shares or guaranteed dilution. The denominator, terms and future funding states must stay separate.

Why This Is the Best Opportunity Right Now

JAGX ranks first for information value because recent primary filings expose a conditional share-supply path that a price-only or stale market-cap screen would miss. The Sep. 29 proxy quantifies exchange sensitivities and says the Series Q exchange price depends on the future market price. The Oct. 2 release then adds a distinct Series R distribution, but defers its key terms to a future Form 8-K. The juxtaposition makes the trade question concrete: how much new common can exist, when, and for which claims? The present record cannot answer the Series R part.

SXTP is the more immediate binary catalyst, but its Oct. 6 randomized-trial interim data could be favorable and stop the trial early. NRSN’s listing notice is also fresh, yet an issuer-confirmed timely appeal request can stay suspension while its Phase 3 program creates upside. Both fail the short’s adverse-bound gate. SPY is only the broad-market control.

JAGX had already fallen from an observed $12.10 intraday high on Sep. 25 to a $3.66 Oct. 2 close, a 69.8% decline. The regular-session drop on Oct. 2 preceded the 8:35 p.m. EDT release timestamp and cannot be assigned to that dividend announcement. No independent consensus source shows how much dilution, debt conversion or dividend protection is currently priced.

Why This Can Move More Than 5% Soon

The first post-announcement regular session is Monday Oct. 5. Eligibility for Series R is based on holding voting common or specified warrants at the Oct. 13 close; payment is scheduled for Oct. 15; each Series R preferred share is scheduled to convert into five common shares on Nov. 2. The release does not state the preferred amount per common share, so neither the aggregate conversion shares nor any short-side distribution obligation can yet be calculated.

The separate Nov. 6 special meeting asks stockholders to approve issuance of common shares on exchange of Series Q preferred and CVP debt. The proxy states that, if approved, the company may make exchanges from time to time at its discretion, subject to the required amendments and transaction documents. It illustrates 1.81 million, 3.39 million and 25.39 million shares at $14, $7.50 and $1 hypothetical exchange prices, respectively. These illustrations are neither a commitment to exchange nor an announced price target. A higher exchange price means fewer shares for the same claim, while lower prices can imply a much larger share count; that reflexivity creates squeeze and repricing risk in both directions.

10/5 Asymmetry Gate

The model uses the $3.66 Oct. 2 regular close as a reference, not an entry, through the Nov. 2 scheduled Series R conversion date. The issuer-hosted historical lookup reports an Oct. 2 session low/high of $3.50/$4.30 on its post-split basis. The same market-history series reports a $12.10 high on Sep. 25, also after the Sep. 17 reverse split; it is used only as a recent rebound stress, not fair value or a price cap.

The base case is unchanged at $3.66, a 0% decline. The lowest same-session stress is $3.50, only a 4.4% short gain. A reprint of the reported $41.53 Sep. 22 intraday high is a +1,034.7% adverse move. This is a low-confidence historical stress, not fair value or a ceiling. Gross base/adverse reward-risk is 0:1. The short fails 10/5 before borrow, spread, slippage, fees or corporate-action obligations.

The Setup

Series R dividend state. On Oct. 2, Jaguar announced a dividend of Series R Convertible Preferred Stock to eligible voting-common and specified warrant holders at the Oct. 13 record date. The release schedules payment for Oct. 15 and conversion of each Series R preferred share into five common shares on Nov. 2. Management says the distribution is intended to protect shareholders against potential dilution while the company evaluates strategic alternatives. The release does not state how many Series R preferred shares each existing common share receives. The issuer directs investors to a future Form 8-K for the complete terms; as of this research cutoff, its filings page displayed the Sep. 29 preliminary proxy as the latest filing.

Recent denominator and lender exchanges. Jaguar announced a 1-for-15 reverse split effective Sep. 17. A Sep. 24 Form 8-K says it issued 547,898 shares to reduce the 2025 note by $5.050 million and 182,091 shares to reduce the 2021 note by $1.678 million; the 2025 note was paid and cancelled. It reported 1,463,958 common shares outstanding as of Sep. 24. A Sep. 25 filing then disclosed another 481,584 shares exchanged for $3.4 million of 2021-note balance and a total 1,945,542 common shares outstanding as of Sep. 25. Thus 1,211,573 shares were issued across these disclosed exchanges for about $10.128 million of claim reduction. Debt relief is not cash raised, and issuance is not proof of resale.

Nov. 6 vote and conditional exchange. The Sep. 29 amended preliminary proxy reports 899.82 Series Q preferred shares and about $2.895 million of CVP debt outstanding on Sep. 25. It says the Series Q exchange price is based on the lower of a closing price or the preceding five-day average at the time of exchange; the CVP debt exchange uses the applicable Minimum Price. If the proposal is approved and all claims are exchanged, Jaguar illustrates 25.391 million common shares (92.9% of the pro forma count) at a $1 hypothetical exchange price, 3.385 million (63.5%) at $7.50, and 1.814 million (48.3%) at $14. The proxy identifies these as examples, not predictions, and says the exact dilution cannot be determined in advance. Stockholder approval is required; the company does not promise to exchange everything.

The same proxy seeks approval to reprice certain warrants to $1, expand the stock plan to 14% of fully diluted common, grant board discretion for a 1-for-2 to 1-for-150 reverse split, and lower the ELOC floor price from $16.50 to an unfilled value. These are separate proposals and state changes, not completed issuance. At the Oct. 2 $3.66 close, the disclosed ELOC floor for fixed and VWAP purchases was not met; any floor change remains subject to the Nov. 6 vote and other agreement terms.

Cash and claim context. The June 30 Form 10-Q reported $3.788 million cash and $2.802 million restricted cash. Six-month operating cash flow was positive $3.492 million, but included the $19 million Woodward/Future Pak license package recognized in Q1: $16 million upfront plus $3 million for termination of a repurchase option. The company said historical resources were insufficient to fund a one-year operating plan and going-concern doubt remained. The recent September note exchanges materially changed the debt/share state after quarter-end. June cash and operating cash flow are not current liquidity after those settlements.

The Market Price

Jaguar’s own historical lookup, based on LSEG, reports the Oct. 2 regular close at $3.66, down $0.29 / 7.34%, with high/low $4.30 / $3.50 and 577,650 shares traded. StockAnalysis reports the same close and range with 575,668 shares; this 0.3% volume difference is not used to infer positioning. The regular session ended at 4 p.m. EDT.

StockAnalysis separately displayed $3.68 at 7:59 p.m. EDT, about 36 minutes before the 8:35 p.m. EDT release timestamp carried by news-distribution services. That after-hours mark is pre-disclosure context, not a reaction price. No post-release trade, bid/ask, spread, depth or price acceptance was verified. The first regular session after the release is Oct. 5.

The issuer’s Sep. 25 common count times the Oct. 2 quote would equal about $7.12 million, but it combines dates and must not be presented as a current market capitalization. Vendor pages still show roughly 520,000 shares and about $1.9 million market value, consistent with the split-date count rather than the later issuer filings. No current EV, float, or short-interest ratio is used.

The Mispricing

The short case is that serial debt-for-equity exchanges and an issuer-described dilution-protection dividend arrive alongside a proxy that asks stockholders to approve potentially large future exchanges into common stock. At the $1 hypothetical price, the proxy says full exchange could represent 92.9% of the pro forma common count. The current quote is $3.66, far below the $7.06 Nasdaq Minimum Price cited for Sep. 25, but that price reference does not set the future exchange price or prove immediate issuance.

The strongest opposing view is that the proxy’s exchange scenario retires $2.895 million in claims, the recent $5.05 million 2025 note was cancelled, and the preferred distribution is presented by management as protection against dilution. JAGX had also received a one-time $19 million licensing package earlier in 2026. The market may already discount future exchange supply after the price fell 69.8% from the Sep. 25 high. No independent consensus evidence measures the market’s expected exchange price, vote probability, or Series R amount. Therefore the disagreement is informational and event-driven, not a claim that a measured fair value is wrong.

The Positioning

The recent issuer share exchanges establish supply issuance, but not whether Streeterville sold any shares. The agreement permits shares to become free trading after brokerage and clearing approval; no actual resale record, current beneficial ownership, borrow inventory, fee, utilization, recall terms, short-interest settlement date, options positioning, or holder-flow source was verified. Daily price and volume show volatility and attention, not who owns or must cover the stock.

Positioning score is capped at 2/5. One market-data provider lists 520,140 shares outstanding and 326,132 short shares (62.70% of its denominator), but does not give a settlement date on the page; both the share count and the percentage conflict with the issuer’s later Sep. 25 count. Neither is used to claim current crowding.

The Catalyst

  1. Oct. 5 post-release regular session: verify opening gap, regular-session close, spread, depth, volume quality and venue. Do not attribute Oct. 2 price action to an 8:35 p.m. EDT release.
  2. Series R designation, before Oct. 13: obtain the preferred shares-per-common ratio, liquidation/conversion terms, adjustment provisions, transferability and any board discretion from the promised Form 8-K. Reconcile eligibility for common and warrants.
  3. Record and payment, Oct. 13 / Oct. 15: distinguish entitlement from actual delivery; confirm transfer-agent and broker processing, any due-bill mechanics, and actual preferred shares delivered.
  4. Nov. 2 conversion: verify actual common shares issued from Series R and report the post-conversion denominator; five common shares per preferred is only one part of the conversion arithmetic.
  5. Nov. 6 shareholder meeting: verify the vote on CVP exchange authority, warrant repricing, stock-plan increase, reverse-split discretion and ELOC-floor amendment. Approved authority does not mean an exchange, warrant exercise, ELOC purchase notice, share settlement or cash receipt has occurred.

Cheapest falsification test: obtain the Series R certificate, a fresh regular-session quote/borrow package, and the next post-Sep. 25 issuer share count. Without the dividend ratio and a re-traded regular-session price, neither a diluted denominator nor an executable entry can be responsibly calculated.

The Payoff

The short-favorable stress is a move to the Oct. 2 session low of $3.50, a 4.4% decline. The highest-probability base holds the $3.66 reference because the Oct. 2 release was not yet in a regular-session price and the Series R amount is unknown. The short-worst modeled stress is a reprint of the reported $41.53 Sep. 22 intraday high, a +1,034.7% adverse rise. This extreme low-confidence observation is not fair value or a ceiling; it is a path-risk stress that makes the short’s loss bound indefensible.

Invalidation and execution cancellation are separate. A filed Series R amount that is immaterial or protective, a funded strategic transaction, or failure of the Nov. 6 proposals would invalidate the immediate dilution premise. Missing borrow, a widened spread, a recall or a halt would cancel any hypothetical entry even if long-run financing risk remained.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Horizon Conditions Evidence Quality
Top Case 10% $3.50 +4.4% short price return Through Nov. 2, 2026 Return to the Oct. 2 low; no quantified dilution assumption Low
Base Case 85% $3.66 0.0% Through Nov. 2, 2026 Preferred terms and actual exchange state remain unresolved; no material repricing from the reference Low
Bottom Case 5% $41.53 -1,034.7% short price return Through Nov. 2, 2026 Reprint of the reported Sep. 22 post-split intraday high; low-confidence tail stress, not fair value or a cap Low
Invalidation n/a Non-material Series R amount, funded strategic deal, or a material terms change before Nov. 2 Not modeled Before Nov. 2, 2026 The assumed near-term common-supply path changes Medium

Probability-weighted expected value: $5.5375 weighted reference price; approximately -51.3% gross expected short price return before borrow, recall, fees, spread, slippage or corporate-action obligations. Probabilities are low-confidence analyst judgment, not calibrated frequencies: the 10% favorable case is only a return to the same-session low, the 85% flat case reflects absent Series R terms and no new regular-session response, and the 5% tail weight recognizes the reported Sep. 22 spike and September volatility rather than predicting recurrence.

Current market level and timestamp: $3.66, Oct. 2, 2026 4:00 p.m. EDT regular close. The $3.68 after-hours display at 7:59 p.m. EDT preceded the after-close release.

Primary instrument: JAGX common stock, Nasdaq, USD; research only.

10/5 favorable base move: 0.0% decline.

10/5 credible adverse move: +1,034.7% to the reported $41.53 Sep. 22 high stress; this is not a maximum loss estimate.

10/5 measurement basis: reference-only; no verified post-disclosure entry.

10/5 status: Reject.

Confidence: Low. Primary filings quantify several claims, but the Series R amount, current denominator, market acceptance and short execution state are missing.

Sensitivity: Reducing bottom-case probability from 5% to 2% and moving the difference to base (10%/88%/2%) gives a weighted price of $4.4014 and approximately -20.3% gross expected short return. The conclusion remains negative; the current data do not support a tighter adverse bound. Exchange-share illustrations in the proxy are contingent and cannot be translated into a price target without a post-vote exchange decision, share state, cash/claim bridge and market response.

The Kill Shot

The strongest counterparty view is that the common has already fallen sharply, a $5.05 million 2025 note was extinguished and a further $5.078 million of 2021-note balance was reduced through recent share exchanges. The $19 million licensing package improved Q2 cash conversion, and management says Series R is intended to protect existing holders. A strategic asset transaction or a small Series R distribution could make the common more resilient than the dilution headline suggests.

The most fragile short assumption is that the undefined Series R amount and the conditional CVP exchange authority will translate into near-term resale pressure. The Nov. 6 vote has not occurred; the proxy says exchange price is determined later and exchange shares are not automatically issued. A short can lose on a strategic announcement or record-date squeeze before either security conversion completes. The cheapest decisive test is the Series R designation and next filed denominator, not another percentage scraped from a stale short-interest page.

What Could Go Wrong

  • Series R’s share-per-common amount is small, non-dilutive, or accompanied by terms that support market demand.
  • CVP exchange proposals fail at the Nov. 6 meeting, are amended, or are not exercised; recent debt cancellation reduces claims without future exchange shares.
  • A funded strategic transaction or licensing payment arrives before further common supply.
  • The exchangeable debt is retired at a high share price and produces fewer shares than the low-price scenario table; proxy calculations are explicitly hypothetical.
  • The outstanding Series R distribution imposes a due-bill or manufactured-payment obligation on short positions, or borrow is recalled before conversion.
  • JAGX repeats the extreme post-split volatility seen in September; $41.53 is a reported stress, not an upper bound, and short losses are theoretically unbounded.
  • A halt, split action, wide spread, poor depth or stale denominator prevents exit at any modeled level.

What Would Prove This Wrong

The dilution concern would be wrong if the Series R certificate shows a negligible common-equivalent amount, the Nov. 6 exchange proposals fail, later filings show no additional issued shares and strategic funding is completed without material common issuance. Conversely, a confirmed, settled exchange and subsequent holder resale would materially strengthen the supply thesis but still would not make a short executable absent locate, borrow/recall, quote, spread, depth and exit data. No new trade qualifies unless a fresh map shows at least a 10% highest-probability decline, an adverse rise no greater than 5%, at least 2:1 gross reward/risk and positive expected value after costs.

Risk Audit

  • Capital structure: Sep. 23-25 common-share exchanges reduced notes by about $10.128M while issuing 1.212M shares. The current 1.946M filed denominator is Sep. 25 dated; do not take vendor 520K float fields as current.
  • Conditional conversion: the proxy’s 48.3%-92.9% post-exchange dilution examples depend on hypothetical exchange price, full exchange and shareholder approval. They do not represent current float or a scheduled issuance.
  • Cash quality: $3.8M unrestricted and $2.8M restricted cash are June figures. Positive first-half operating cash included one-time license fees; management still reported one-year funding doubt.
  • New dividend: Oct. 2 press release does not state Series R shares per eligible common share. Five common shares per preferred does not tell how many preferred shares are distributed.
  • Market reaction: the Oct. 2 regular close and later 7:59 p.m. quote preceded the 8:35 p.m. EDT release; there is no verified post-release price acceptance.
  • Short mechanics: no current locate, borrow fee, recall terms, spread, depth, holder flows, settlement route or corporate-action handling confirmed.

Best Trade Strategy

No trade. Keep entry.price null and execution disabled. Do not short because of the phrase “dilution protection,” because recent exchange shares were issued, or because a proxy shows a large potential dilution scenario. Reassess after Oct. 5 regular-session acceptance, filing of the Series R certificate, actual Oct. 15 distribution, Nov. 2 conversion and Nov. 6 vote. A future expression requires the actual Series R ratio, current filed share count, verified exchange/settlement/resale state, a fresh regular-session quote, locate, borrow/recall, spread, depth, venue and exit capacity, plus a new 10/5 map. No options, leverage, margin, market orders, price floors or no-locate shorting.

Sources

Research Quality Scorecard

Criterion Score Evidence basis / deduction
Market disagreement 3/5 Fresh dividend and proxy supply claims, but no independent consensus expectation and the Series R amount is missing
Evidence base 4/5 Fresh primary October release and September filings; new security designation and post-Sep. 25 share count are unavailable
Positioning and flows 2/5 1.212M recent issuer shares evidenced; no resale, borrow, current short interest or holder-flow data
Catalyst path 4/5 Oct. 5 response, Oct. 13 record, Oct. 15 payment, Nov. 2 conversion and Nov. 6 vote are dated; each has unresolved conditions
Payoff architecture 2/5 Flat base, negative weighted reference return, 0:1 ratio and adverse stress above 5%; no executable entry
Invalidation discipline 5/5 Terms, vote, exchange price, settlement, resale and cash/share-count filings are explicit tests
Differentiated insight 4/5 Separates the five-common conversion ratio from preferred-per-common distribution ratio and debt extinguishment from cash
Client value 4/5 Corrects stale share fields and prevents an “anti-dilution” label or conditional proxy table from becoming a short order
Total 28/40 Reject controls because base decline is below 10%, adverse stress exceeds 5%, and gross base/adverse is 0:1.

Bottom Line

JAGX’s Oct. 2 announcement adds a Series R record, payment and conversion path, but the number of preferred shares issued per existing common share was not disclosed in the release or listed filings by this review. Meanwhile, the issuer reported 1.946 million common shares outstanding after late-September debt exchanges, and its proxy illustrates conditional future dilution ranging from 48.3% to 92.9% of post-exchange common under hypothetical terms. At the latest $3.66 regular close, the base short case is flat and a reported $41.53 high is a +1,034.7% adverse stress. Reject the short.

AI Illustration Prompt

Create a restrained institutional editorial illustration for The Mispricing Desk: a post-split JAGX share certificate stamped “1,945,542 SHARES — SEP 25” beside a blank Series R certificate whose missing line reads “PREFERRED SHARES PER COMMON: NOT FILED.” Put a distinct calendar with “OCT 13 RECORD,” “OCT 15 DISTRIBUTION,” “NOV 2 CONVERSION: 5 COMMON / PREFERRED SHARE,” and “NOV 6 VOTE.” In a second ledger show “1.212M COMMON SHARES ISSUED” against “$10.128M NOTE CLAIMS REDUCED,” labeled “DEBT EXCHANGE, NOT CASH.” Add a small price tape: “$3.66 OCT 2 CLOSE / $41.53 SEP 22 HIGH — REFERENCE STRESS.” Use slate, cream, paper-white and a restrained copper accent; avoid arrows, price-floor imagery and any implication the Series R dilution is quantified. Add a subtle readable “The Mispricing Desk” watermark.